The seasonal influenza vaccines market is largely dominated by big pharmaceutical companies and expected to witness the entry of smaller companies, according to a report by GlobalData.

Titled: 'PharmaPoint: Seasonal Influenza Vaccines – Global Drug Forecast and Market Analysis to 2025’, the report projects the influenza vaccines market to reach $4.3bn by 2025 across the seven major pharmaceutical markets (7MM) of the US, France, Germany, Italy, Spain, the UK and Japan.

Big pharma companies such as Sanofi, GlaxoSmithKline (GSK), AstraZeneca / MedImmune, Novartis, and CSL Limited / Sequris have been dominating the influenza vaccines market for a decade. In recent years, however, smaller companies such Protein Sciences Corporation, Mylan and Mitsubishi Tanabe Pharma have entered the market and acquired significant market share.

With the exit of Novartis in 2015, the market is currently left with just four established big pharmaceutical companies that are adopting various marketing strategies to remain competitive in the market, according to Christopher J. Pace, PhD, GlobalData’s Director of Infectious Diseases.

" … CSL / Seqirus promotes the superior efficacy of its quadrivalent cell culture-based vaccines Flucelvax and Fluad over standard vaccines."

For example, CSL / Seqirus promotes the superior efficacy of its quadrivalent cell culture-based vaccines Flucelvax and Fluad over standard vaccines.

Similarly, GSK flagship product Fluarix Tetra has a strong presence in the market and has been positioned to compete with Sanofi’s Fluzone Quadrivalent in the US and Vaxigrip in Europe.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AstraZeneca has tried to market its FluMist product by focusing on the benefits of a nasal spray over intramuscular injectable vaccines. The US Centers for Disease Control and Prevention’s decision to recommend against the use of FluMist, however, is expected to significantly affect the product's future sales.

Smaller companies are expected to play a key role in the market by adopting cell culture-based manufacturing methods although big pharmaceutical companies are not expected to lose their market leadership, the report adds.